|Title||Director of Liver Surgery Department, Professor|
Professor Min-shan Chen is currently the director of Liver Surgery Department. He has been leading an experienced multi-disciplinary team (MDT) for the diagnosis and treatment of liver cancers. The MDT provides individualized case management for patients, whose modalities include: laparoscopic hepatectomy, robotic-assisted laparoscopic hepatectomy, thermal ablation, transarterial intervention, etc. He has published more than 100 papers as the corresponding author or first author, and 6 of which were cited by NCCN guidelines for liver cancer. Professor Chen is also the principle investigator of several multi-center researches, and the recipient of more than 10 national grants. To recognize his substantial contribution to the research field, he was listed as one of the Highly Cited Researchers by Elsevier.
Multi-disciplinary treatment of hepatocellular carcinoma, including minimally invasive surgery, thermal ablation, and transarterial intervention modalities.
M.D. Sun Yat-Sen University of Medical Sciences, 1981-1987
Ph.D. Oncology, Sun Yat-Sen University of Medical Sciences, 1996-2000
1. Peng Z W#, Zhang Y J#, Chen M S*, Xu L, Liang H H, Lin X J, Guo R P, Zhang Y Q, Lau W Y. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial [J]. J Clin Oncol, 2013, 31(4): 426-432. (IF 28.245)
2. Xu L#, Peng Z W#, Chen M S*, Shi M, Zhang Y J, Guo R P, Lin X J, Lau W Y. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization [J]. J Hepatol, 2015, 63(1): 122-130. (IF=18.946)
3. Fang J H#, Xu L#, Shang L R#, Pan C Z, Ding J, Tang Y Q, Liu H, Liu C X, Zheng J L, Zhang Y J, Zhou Z G, Xu J, Zheng L, Chen M S*, Zhuang S M*. Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma [J]. Hepatology, 2019, 70(3): 824-839. (IF=14.971)
4. Lian Y F#, Huang Y L#, Zhang Y J#, Chen D M, Wang J L, Wei H, Bi Y H, Jiang Z W, Li P, Chen M S*, Huang Y H*. CACYBP Enhances Cytoplasmic Retention of P27(Kip1) to Promote Hepatocellular Carcinoma Progression in the Absence of RNF41 Mediated Degradation [J]. Theranostics, 2019, 9(26): 8392-8408. (IF=8.063)
5. Chen M S#*, Li J Q, Zheng Y, Guo R P, Liang H H, Zhang Y Q, Lin X J, Lau W Y. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma [J]. Ann Surg, 2006, 243(3): 321-328. (IF 7.6).
6. Zhang Y J#, Liang H H, Chen M S*, Guo R P, Li J Q, Zheng Y, Zhang Y Q, Lau W Y. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial [J]. Radiology, 2007, 244(2): 599-607. (IF 7.608)
7. Peng Z W#, Lin X J, Zhang Y J, Liang H H, Guo R P, Shi M, Chen M S*. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study [J]. Radiology, 2012, 262(3): 1022-1033. (IF 7.608)
8. Peng Z W#, Zhang Y J, Liang H H, Lin X J, Guo R P, Chen M S*. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial [J]. Radiology, 2012, 262(2): 689-700. (IF 7.608)
9. Chen J#, Peng K#, Hu D, Shen J, Zhou Z, Xu L, Chen J, Pan Y, Wang J, Zhang Y*, Chen M*. Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation [J]. Cancers (Basel), 2018, 10(10) (IF=6.162)
10. Peng Z W#*, Liu F R#, Ye S, Xu L, Zhang Y J, Liang H H, Lin X J, Lau W Y, Chen M S*. Radiofrequency ablation versus open hepatic resection for elderly patients (> 65 years) with very early or early hepatocellular carcinoma [J]. Cancer, 2013, 119(21): 3812-3820. (IF: 6.102)
Updated June 2020 by International Office, Sun Yat-sen University Cancer Center
|Title||Deputy Director and Professor|
Dr. Yunfei Yuan received his medical degree from Zhongshan (Sun Yat-sen) Medical College, Guangzhou, CHINA in 1983. From 1983 to 1986, He got his resident and research training in Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China. Dr Yuan entered the same university for his postgraduate study under the supervision of Professor Ji-Fu Wang in 1986 and got his Master of Medicine in 1989.
He has been a surgeon in the department of abdominal oncology in this cancer center from 1989 to 1997 and the department of hepatobiliary oncology in this cancer center since 1997. Dr. Yuan was promoted to associate professor in 1997 and full professor in 2004.
Dr. Yuan’s clinical practice and research focuses on hepatic and biliary malignancies. He is skillful at orthotopic liver transplantation and hepatectomy, including left (right) hemi-hepatectomy or trisegmentectomy and two-step hepatectomy, and pancreatoduodenectomy. He also performs trans catheter hepatic artery chemoembolization for liver cancer. He is the key member of Multi-Disciplinary Team (MDT) for the treantment of colorectal cancer liver metastases (CRLM) and finish the resection of CRLM of most cases in this cancer center. He is the pioneer in China to evaluate the hepatic functional reserve for patients with hepatocellular carcinoma with one parameter, retention rate of Indocyanine Green at 15 minutes (ICGR15), which help to decrease the morbidity of hepatic failure after hepatectomy or chemoembolization.
Recommended by Ministry of Health of CHINA, Dr Yuan got World Health Organization Fellowship in 1998. He worked in Baylor College of Medicine (BCM) from August 1998 to July 2000 and M.D. Anderson Cancer Center (MDA) from August 2000 to August 2001 as visiting scholar, both in Houston, Texas, USA. He got training in tumor molecular biology, as well as in clinics of hepatic and biliary carcinoma. He found that hyper methylation of CpG islands is the mechanism by which SYK is silenced in breast cancer and re-expression of SYK by inhibition of DNA methylation suppresses breast cancer cell invasiveness in MDA.
Currently, Dr. Yuan’s research interest include biomarkers of recurrence and prognosis for HCC, carcinogenesis of HCC, the optimal treatment of hepatocellular carcinoma with portal hypertension. There are 2 associate professors, 5 postgraduate students, 1 technician and 1 research nurse in his group.
1978 - 1983 MB, Zhongshan Medical College
(1) Jian Hong, Yunfei Yuan*, Jianping Wang, Yadi Liao, Ruhai Zou, Chuanlong Zhu, Binkui Li, Yi Liang, Pinzhu Huang, Zongwei Wang, Wenyu Lin, Yixin Zeng, Jia Le Dai, and Raymond T. Chung*. Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma. Cancer Research 2014, 74(6):1845-56 (2014 IF=9.329)
(3) Jun Huang, Qijiong Li, Yun Zheng, Jingxian Shen, Jiliang Qiu, Binkui Li, Ruhai Zou, Jianping Wang and Yunfei Yuan*. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature. BMC Cancer 2014, 14:818. (2014 IF=3.362)
(4) Bin-Kui Li, Pin-Zhu Huang, Ji-Liang Qiu, Ya-Di Liao, Jian Hong and Yun-Fei Yuan*. Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma. Diagnostic Pathology 2014, 9:226.(2014 IF=2.597)
(5) Cong Li, Yangkui Gu, Ming Zhao, Yunfei Yuan, Fenghua Wang, Zhiqiang Wang, Wang Li, Huiyan Luo, Cui Chen, Gong Chen, Peirong Ding, Xiaojun Wu, Zhenhai Lu, Zhizhong Pan, Ruihua Xu, Youjian He, Desen Wan, Yuhong Li. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer chemotherapy and pharmacology. 2014, 4(5):1079-87.
(6) Stella Chai, Man Tong, Kai Yu Ng, Pak Shing Kwan, Yuen Piu Chan, Tsun Ming Fung, Terence K Lee, Nathalie Wong, Dan Xie, Yun-Fei Yuan, Xin-Yuan Guan, Stephanie Ma. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget. 2014, 5(14):5725-35.
(7) Longhui Cao, Yi Chang, Wenqian Lin, Jianhua Zhou, Hongying Tan, Yunfei Yuan, Weian Zeng. Long-term survival after resection of hepatocelluar carcinoma: a potential risk associated with the choice of postoperative analgesia. Anesthesia & Analgesia. 2014, 118(6):1309-16.
(8) Yin Xie, Rong-Rong Wei, Guo-Liang Huang, Mei-Yin Zhang, Yun-Fei Yuan, Hui-Yun Wang. Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. Medical Oncology. 2014, 31(3):844.
(9) Ming Liu, Yan Li, Leilei Chen, Tim Hon Man Chan, Yangyang Song, Li Fu, Ting-Ting Zeng, Yong-Dong Dai, Ying-Hui Zhu, Juan Chen, Yun-Fei Yuan, Xin-Yuan Guan. Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma. Gastroenterology. 2014, 146(4):1084-96.
(10) Lulu Liu, Yongdong Dai, Jinna Chen, Tingting Zeng, Yan Li, Leilei Chen, Ying-Hui Zhu, Jiangchao Li, Stephanie Ma, Dan Xie, Yun-Fei Yuan, Xin-Yuan Guan. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail signaling. Hepatology. 2014, 59(2):531-43.
(11) Tim Hon Man Chan, Chi Ho Lin, Lihua Qi, Jing Fei, Yan Li, Kol Jia Yong, Ming Liu, Yangyang Song, Raymond Kwok Kei Chow, Vanessa Hui En Ng, Yun-Fei Yuan, Daniel G Tenen, Xin-Yuan Guan, Leilei Chen. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 2014, 63(5):832-43.
(12) Wei He, Qingli Zeng, Yun Zheng, Meixian Chen, Jingxian Shen, Jiliang Qiu, Miao Chen, Ruhai Zou, Yadi Liao, Qijiong Li, Xianqiu Wu, Binkui Li* and Yun-Fei Yuan*. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer 2015, 15:263. (2014 IF=3.362)
(13) Xianqiu Wu, Binkui Li, Jiliang Qiu, Jingxian Shen, Yun Zheng, Qijong Li, Yadi Liao, Wei He, Ruhai Zou and Yunfei Yuan*. Hepatectomy versus hepatectomy with lymphadenectomy in hepatocellular carcinoma – A prospective, randomized controlled clinical trial. Journal of Clinical Gastroenterology 2015;49:520-528（2014 IF=3.498）
(14) Jiliang Qiu, Yun Zheng, Jingxian Shen, Zeng QingAn, Ruhai Zou, Yadi Liao, Wei He, Qijiong Li, Guihua Chen, Binkui Li, Yunfei Yuan*. Resection versus ablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study. Surgery. 2015, 158(5):1235-1243.（2014 IF=3.38）
(15) Lingxi Jiang, Dora Lai-Wan Kwong, Yan Li, Ming Liu, Yun-Fei Yuan, Li Fu, Xin-Yuan Guan*. HBP21, a chaperone of heat shock protein 70, functions as a tumor suppressor in hepatocellular carcinoma. Carcinogenesis. 2015, 36(10):1111-20.
(16) Yangyang Song, Guangjin Pan, Leilei Chen, Stephanie Ma, Tingting Zeng, Tim Hon Man Chan, Lei Li, Qizhou Lian, Raymond Chow, Xiujuan Cai, Yan Li, Ming Liu, Yun Li, Yinghui Zhu, Nathalie Wong, Yun-Fei Yuan, Duanqing Pei, Xin-Yuan Guan*. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells. Gastroenterology. 2015, 149(4):1068-81.
(17) Man Tong, Tsun-Ming Fung, Steve T Luk, Kai-Yu Ng, Terence K Lee, Chi-Ho Lin, Judy W Yam, Kwok Wah Chan, Fai Ng, Bo-Jian Zheng, Yun-Fei Yuan, Dan Xie, Chung-Mau Lo, Kwan Man, Xin-Yuan Guan, Stephanie Ma. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma. Stem Cell Reports. 2015, 5(1):45-59.
(18) Xue-Jia Lin, Yutian Chong, Zhi-Wei Guo, Chen Xie, Xiao-Jing Yang, Qi Zhang, Sheng-Ping Li, Yujuan Xiong, Yunfei Yuan, Jun Min, Wei-Hua Jia, Yusheng Jie, Min-Shan Chen, Mei-Xian Chen, Jian-Hong Fang, Chunxian Zeng, Yaojun Zhang, Rong-Ping Guo, Yuankai Wu, Guoli Lin, Limin Zheng, Shi-Mei Zhuang. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. The Lancet Oncology. 2015, 16(7):804-15.
(19) Zhong-Guo Zhou, Xing-Rong Zheng, Qian Zhou, Ming Shi, Yao-Jun Zhang, Rong-Ping Guo, Yun-Fei Yuan, Min-Shan Chen, Xiao-Jun Lin, Xiang-Ming Lao, Sheng-Ping Li. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chinese Journal of Cancer. 2015, 34(5):205-16.
(20) Jian-Hong Fang, Hui-Chao Zhou, Chong Zhang, Li-Ru Shang, Lei Zhang, Jing Xu, Limin Zheng, Yunfei Yuan, Rong-Ping Guo, Wei-Hua Jia, Jing-Ping Yun, Min-Shan Chen, Yaojun Zhang, Shi-Mei Zhuang. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology. 2015, 62(2):452-65.
(21) Fang Zheng, Yi-Ji Liao, Mu-Yan Cai, Tian-Hao Liu, Shu-Peng Chen, Pei-Hong Wu, Long Wu, Xiu-Wu Bian, Xin-Yuan Guan, Yi-Xin Zeng, Yun-Fei Yuan, Hsiang-Fu Kung, Dan Xie. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. PLoS Genetics. 2015, 11(2):e1004873.
(22) Jian Wang, Ming Liu, Leilei Chen, Tim Hon Man Chan, Lingxi Jiang, Yun-Fei Yuan, Xin-Yuan Guan. Overexpression of N-terminal kinase like gene promotes tumorigenicity of hepatocellular carcinoma by regulating cell cycle progression and cell motility. Oncotarget. 2015, 6(3):1618-30.
(23) Sheng-Long Ye*, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, Guoliang Shao, Qiang Xia, Yajin Chen, Jijin Yang, Xiaxing Deng, Yunpeng Liu, Yunfei Yuan, Zhiren Fu, Keiko Nakajima, Christina SM YIP, Zhengguang Lu. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget. 2015, 7(6):6639
(24) Pinghua Yang, Jiliang Qiu, Jun Li, Dong Wu, Xuying Wan, Wan Yee Lau, Yunfei Yuan*, and Feng Shen*. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Annals of Surgery 2016, 263(4):778–786 (2014 IF=8.327)
|Title||Deputy Director and Professor|
Dr. Rong-ping Guo is professor, PhD supervisor and vice-director of Department of Hepatobiliary Tumor of Sun Yat-sen University Cancer Center. Dr. Guo obtained his Bachelor in Medicine (equivalent to MD in the US) and Master at Sun Yat-sen University of Medical Sciences, P. R. China in 1988 and 1994, respectively. From 1988,Dr.Guo was engage in the clinical and theoretical research of hepatobiliary tumor. Dr.Guo worked as visiting bachelor in Queen Mary Hospital of Hong Kong University and Prince of Wales Hospital of Chinese University of Hong Kong from Apr 2003 to Dec 2003. After then he worked as visiting bachelor in Organ Transplantation Center of University of Pittsburgh from Apr 2004 to Sep 2004. Dr.Guo now lead a research team in Department of Hepatobiliary Tumor and specialize in diagnosis and treatment of hepatobiliary tumor, including surgery, vascular intervention, local ablation and liver transplantation. The work of Dr.Guo and his team has got support by different fund including National natural science foundation of China and has published more than 10 SCI papers.
Diagnosis and treatment of hepatobiliary tumor, including surgery, vascular intervention, local ablation ,target therapy and liver transplantation, especially the multidisciplinary treatments for advanced HCC. His basic research fields including tumorigenesis, angiogenesis and metastasis of HCC
1982-1988 Faculty of clinical medicine of Sun Yat-sen University of Medical Sciences, Bachelor
1991-1994 Faculty of Clinical Oncology of Sun Yat-sen University of Medical Sciences, Master
1.Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Chen ZY, Wei W, Guo ZX, Peng LX, Shi M, Li SH, Xiao CZ, Zhong C, Qian CN, Guo RP.Br J Cancer. 2014 Feb 4;110(3):733-40.
2. Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection.Li SH, Guo ZX, Xiao CZ, Wei W, Shi M, Chen ZY, Cai MY, Zheng L, Guo RP. Asian Pac J Cancer Prev. 2013;14(8):4759-63.
3. Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors.Li SH, Wei W, Guo RP, Shi M, Guo ZX, Chen ZY, Xiao CZ, Cai MY, Zheng L. Med Oncol. 2013 Dec;30(4):696.
4. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.Chen ZY, Shi M, Peng LX, Wei W, Li XJ, Guo ZX, Li SH, Zhong C, Qian CN, Guo RP.J Transl Med. 2012 Dec 10;10:245
5. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial.Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, Luo J, Xu L, Zou RH, Lin XJ, Zhang YQ.J Natl Cancer Inst. 2013 Jan 2;105(1):59-68.
6. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus.Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Cancer. 2012 Oct 1;118(19):4725-36.
7. Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection.Zhong C, Wei W, Su XK, Li HD, Xu FB, Guo RP. Hepatogastroenterology. 2012 Jan-Feb;59(113):93-7.
8. Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection.Chen ZY, Wei W, Guo ZX, Lin JR, Shi M, Guo RP. J Gastroenterol Hepatol. 2011 May;26(5):866-74.
9. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis. Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, Shi M. Radiology. 2011 Apr;259(1):286-95.
10. ransarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study.Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M. Ann Surg Oncol. 2011 Feb;18(2):413-20
11. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, Zhang YQ. J Cancer Res Clin Oncol. 2009 Oct;135(10):1437-45.
12. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ. Ann Surg. 2007 Jan;245(1):36-43.
Updated by International Office, Sun Yat-sen University Cancer Center
|Title||Professor and Deputy Director of Liver Surgery Department|
Dr. Binkui Li is currently a professor, PhD supervisor and deputy director of Liver Surgery Department, Sun Yat-sen University Cancer Center. He specializes in multidisciplinary treatment of liver cancers, including surgery, vascular interventional therapy, targeted and immunotherapy. Dr. Li has devoted himself to improving patients’ curative effects of disease and quality of life by developing a multidisciplinary, individualized, systemic treatment program for every patient. He focuses on conversion therapy for advanced liver cancer, which creates surgery opportunities for some initially unresectable liver cancers. As an expert member of Multi-Disciplinary Team (MDT) for colorectal cancer, Dr. Li is also skilled in surgery of liver metastasis from colorectal cancer. Dr. Li had been a visiting scholar in MD Anderson Cancer Center from 2013 to 2014. In 2018, Dr. Li was awarded the Outstanding Young Medical Talents in Guangdong Province. Besides, he has undertaken researches of National Natural Science Foundation of China, Key projects of Guangdong Provincial Natural Science Foundation, Guangzhou Science and Technology Planning Project, etc.
Pathogenesis of hepatocellular carcinoma; mechanisms of drug resistance towards chemotherapy, targeted therapy and immunotherapy; biomarkers of hepatocellular carcinoma.
Bachelor of Medicine, former Sun Yat-sen University of Medical Sciences, 1996-2001.
Master of Medicine, Sun Yat-sen University Cancer Center, 2001-2003.
Doctor of Medicine, Sun Yat-sen University Cancer Center, 2007-2010.
(2) Mutual regulation of miR-199a-5p and HIF-1α modulates the Warburg effect in hepatocellular carcinoma. J Cancer 2017; 8:940-949.
(3) Nomogram to predict survival of patients with recurrence of hepatocellular carcinoma after surgery. Clin Gastroenterol Hepatol 2018;16:756–764.
(4) Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Aliment Pharmacol Ther 2018; 48(6):671-681.
(5) Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study. Cancer Commun (Lond) 2018;38(1):26.
(6) The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma. J Cancer 2018;9(21):4000-4008.
(7) Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer 2018;18(1):1186.
(8) Extremely high preoperative alpha-fetoprotein level is associated with vascular invasion, non-R0 resection, and poor prognosis in hepatocellular carcinoma patients. Am Surg 2019;85(6):e309-e312.
(9) Resection vs ablation for multifocal hepatocellular carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: a propensity score matching study. J Cancer 2019;10(13):2857-2867.
(10) Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis. Ther Adv Med Oncol 2019; 11: 1-13.
(11) Lipiodol deposition in portal vein tumor thrombus predicts treatment outcome in HCC patients after transarterial chemoembolization. Eur Radiol 2019;29(11):5752-5762.
(12) Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy. Liver Int 2020;40(1):229-239.
(13) Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma. Theranostics 2020;10(12):5209-5224.
(14) Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis. World J Surg Oncol 2020;18(1):98.
(15) Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol 2020;146(10):2669-2680.
Updated October 2020 by International Office, Sun Yat-sen University Cancer Center
|Title||Professor, Chief physician, Doctoral supervisor, winner of the National Science Fund for Distinguished Young Scholars, Leading Medical Talents of Guangdong Province and the Leading Talents of Scientific and Technological Innovation of "Guangdong Special Support Plan"|
Dr. Shi Ming has sufficient experience in liver cancer treatment including locoregional and systemic therapy, like surgery, interventional therapy, target therapy and immunotherapy. He has done a lot of clinical trials and fundamental research focus on optimizing the treatment of stages of B&C HCC. He has numerous publications as corresponding author in the J Clin Oncol, JAMA Oncol, J Natl Cancer Inst, Hepatology, and more. He also figured out that arterial chemotherapy is the critical factor to improve the TACE effect, and proposed a new scheme of hepatic arterial infusion chemotherapy of FOLFOX (FOLFOX-HAIC). Furthermore, he has proposed a new treatment strategy: triple combined therapy (FOLFOX-HAIC + target therapy + immunotherapy) for advanced hepatocellular carcinoma. Additionally, he has done much research to figure out novel biomarkers predicting drug resistance, and discovered a novel therapeutic target of hepatocellular carcinoma. The above research projects have been cited by six international guidelines and consensuses, including the 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights, Guidelines of Chinese society OF clinical oncology (CSCO): Hepatocellular carcinoma, Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO, EASL–EORTC Clinical Practice Guidelines: Management (2012), and Guidelines of the American Society for Interventional Radiology for Liver Cancer (2012).
Therapeutic optimization for the intermediate-advanced hepatocellular carcinoma and the mechanism of the drug resistance in hepatocellular carcinoma.
Graduated from Zhongshan Medical University with a bachelor's degree in clinical medicine. Received his PhD from Sun Yat-sen University in 2005, and was a visiting scholar in Rotenberg Hospital, Diakonie, Germany for general surgery and laparoscopy from 2008 to 2009, and carried out medical research for genetic precision medical research at the National Cancer Center Singapore in 2012.
1) Li QJ#, He MK#, Chen HW#, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M*. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase 3 trial. J Clin Oncol 2021: JCO.21.00608.
Updated November 2021 by International Office, Sun Yat-sen University Cancer Center
|Title||Professor and Chief Physician|
Dr. Xu is currently a Professor and Chief Physician in the Department of Liver Surgery at Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China. She specializes in surgical oncology, and is good at the strategy of multidisciplinary treatment for liver cancer, as well as designing and conducting clinical trials. Her interests include the precise treatment of liver cancer, and translational research on biomarkers to predict therapeutic effect. She has published more than 60 peer-reviewed papers, including some in renowned journals such as Journal of Clinical Oncology, Journal of Hepatology, Hepatology, and Clinical Cancer Research. Dr. Xu also pays close attention to subject protection and ethical issues in clinical research, and serves as an Ethics Committee member of SYSUCC since 2014.
Sep 2014~Aug 2015
Jun 2007~Aug 2007
Sep 2003~Jun 2006
Sep 1997~Jun 2000
Sep 1992~Jun 1997
Publications (first/co-first#/corresponding author*):
(2) Vessels that encapsulate tumor clusters (VETC) pattern is a predictor of sorafenib benefit in patientswith hepatocellular carcinoma. Fang JH#, Xu L#, Shang LR, Pan CZ, Ding J, Tang YQ, Liu H, Liu CX, Zheng JL, Zhang YJ, Zhou ZG, Xu J, Zheng LM, Chen MS*, Zhuang SM*. Hepatology 2019.
(3) A randomized controlled trial on patients withor without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Xu L, Wang J, Kim Y, Shuang ZY, Zhang YJ, Lao XM, Li YQ, Chen MS, Pawlik TM, Xia JC*, Li SP*, Lau WY. OncoImmunology 2016.
(4) Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Xu L, Kim Y, Spolverato G, Gani F, Pawlik TM. Hepatobiliary Surg Nutr 2016.
(5) Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Xu L, Peng ZW, Chen MS*, Shi M, Zhang YJ, Guo RP, Lin XJ, Lau WY. J Hepatol 2015.
(6) Antiviral therapy improves survival of patients with hepatitis B virus-related hepatocellular carcinoma who treated with sorafenib. Xu L, Gao HJ, Huang JT, Wang HY, Zhou ZG, Zhang YJ, Li SP, and Chen MS*. J Gastroenterol Hepatol 2015.
(7) CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. Li L#, Xu L#, Yan J, Zhen ZJ, Ji Y, Liu CQ, Lau WY, Zheng LM*, Xu J*. J Exp Clin Cancer Res 2015.
(8) MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Zhang JP#, Zeng C#, Xu L#, Gong J, Fang JH, and Zhuang SM*. Oncogene. 2014
Updated May 2020 by International Office, Sun Yat-sen University Cancer Center
Dr. Yaojun Zhang is an associated professor of Department of Hepatobiliary Surgery in Sun Yat-sen University Cancer Center (SYSUCC). Dr. Zhang obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University, P. R. China in 2002 and 2014, respectively. After his graduation form medical university, Dr. Zhang started his clinical training at Sun Yat-sen University Cancer Center (SYSUCC), five years for resident training and five years for attending training. His specialist is multi-disciplinary treatment for Hepatocellular Carcinoma (HCC), including surgical resection, local ablation therapy, transcatheter arterial chemoembolization (TACE), systemic chemotherapy, macular target therapy, and so on. Importantly Dr. Zhang is experienced in radiofrequency ablation and laparscopic liver resection for liver tumors.
2.The National Natural Science Foundation of China (NSFC): The relationship and mechanism of intestinal microflora-dependent metabolitic choline- trimethylamine oxide and nonalcoholic fatty liver disease (81472966), 2015-2018, Co-Investigator
3.5010 Program of Sun Yat-Sen University: Re-hepatectomy Versus Radiofrequency ablation combine with transcatheter arterial chemoembolization for recurrent small hepatocellular carcinoma – a prospective randomization control trial, 2013-2013, Co-Investigator
|Research Interest(s)||Hepatocellular carcinoma and mini-invasive treatment.|
Cancer Center, Sun Yat-sen University 9/2009- 7/2014
Degree: Medical Doctor Cancer Center,
Sun Yat-sen University 9/2002- 7/2005
Degree: Medical Master
Sun Yat-sen University 9/1997- 7/2002
Degree: Medical Bachelor
1. Zhenwei Peng, Yaojun Zhang, Minshan Chen*, Li Xu, Huihong Liang, Xiaojun Lin, Rongping Guo, Yaqi Zhang, WanYee Lau. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. Journal of Clinical Oncology. 31(4):426-432, 2013. (Co-author)
2. Yaojun Zhang, Zhenwei Peng, Meixian Chen, Furong Liu, Junting Huang, Li Xu, Yaqi Zhang, Minshan Chen*. Elevated neutrophil to lymphocyte ratio might predict poor prognosis for colorectal liver metastasis after percutaneous radiofrequency ablation. International Journal of Hyperthermia. 28(2):132-140, 2012.
3. Yaojun Zhang, Adam Frampton, Charis Kyriakides, Nagy Habib, Raida Ahmad, Long R Jiao*. Pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: predictors for loco-recurrence and its implications for adjuvant chemoradiotherapy. Journal of Cancer Research and Clinical Oncology. 138(6): 1063-1071, 2012.
4. Yaojun Zhang, Adam E. Frampton, Jack L. Martin, Charis Kyriakides, Panagiotis Vlavianos, Long R Jiao*. 18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors. Nuclear Medicine and Biology. 39(7):982-985, 2012.
5. Yaojun Zhang, Jia Huang, Minshan Chen, Long R Jiao*. Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: a meta-analysis. Pancreatology. 12(3):227-233, 2012.
6. Yaojun Zhang, Adam E. Frampton, Patrizia Cohen, Charis Kyriakides, Jan J. Bong, Nagy A. Habib, Duncan R. C. Spalding, Raida Ahmad, Long R. Jiao*. Tumor infiltration in the medial resection margin predicts survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery. 16(10): 1875-1882, 2012.
7. Yaojun Zhang, Huihong Liang, Minshan Chen*, Rongping Guo, Jinqing Li, Yun Zheng, Yaqi Zhang, WanY. Lau. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology. 2007, 244(2): 599-607.
8. Junting Huang, Yaojun Zhang, Zhenwei Peng, Hengjun Gao, Li Xu, Long R. Jiao, Minshan Chen*. A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. J Cancer Res Clin Oncol. 2013;139(10):1709-19. (Co-author)
9. Hengjun Gao, Yaojun Zhang, Minshan Chen*, Meixian Chen, Junting Huang, Li Xu, WanYee Lau. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. Liver Int. 2014, 34(4):612-620. (Co-author)
10. Jia Huang, Yaojun Zhang, Meixian Chen, Junting Huang, Li Xu, Minsha Chen. Family history of hepatocellulcar carcinoma is not associated with its patients' prognosis after hepatectomy. World J Surg Oncol. 2013, 11(1):280. (Co-author)
11. Jiaqiang Dan, Yaojun Zhang, Zhenwei Peng, Junting Huang, Hengjun Gao, Li Xu, Minshan Chen*. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS ONE. 8(3): e58184. (Co-author)
12. Jiaqiang Dan, Yaojun Zhang, Jungting Huang, Minshan Chen*, Hengjun Gao, Zhenwei Peng, Li Xu, WanYee Lau. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: A retrospective study. European Journal of Surgical Oncology. 2013, 39:865-872. (Co-author)
13. Hengjun Gao, Yaojun Zhang, Huihong Liang, Peng Li, Zhenwei Peng, Xionghao Pang, Minshan Chen*. Radiofrequency ablation does not induce the significant increase of CD4+CD25+Foxp3+ regulatory T cells compared with surgical resection in Hepal-6 tumor model. Arch Immunol Ther Exp (Warsz). 2013, 61(4):333-340. (Co-author)
14. Zhenwei Peng, Yaojun Zhang, Minshan Chen*, Xiaojun Lin, Huihong Liang, Ming Shi. Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: long-term results. European Journal of Surgical Oncology. 36(11):1054-1060, 2010. (Co-author)
15. Haiqing Ma, Yaojun Zhang, Qijing Wang, Yongqiang Li, Jia He, Hui Wang, Jiancong Sun, Ke Pan, Minshan Chen*, Jianchan Xia*. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellulcar carcinoma after radiofrequency ablation. Cancer Biology & Therapy. 9(11):903-907, 2010. (Co-author)
Last Updated: February 2015 by International Office, Sun Yat-sen University Cancer Center
Dr. Yun Zheng is the associate professor of Hepatobiliary Oncology. Dr. Zheng obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 1996 and 2004, respectively. His visiting scientist experience at Cedars-sinai Medical Center in Los Angeles, California from Nov 2010 to Sep 2012 provided him with great opportunities to explore the fields of tumor molecular biology. He also has strong clinical capabilities and proficient techniques for hepatobiliary and pancreas carcinoma. Dr. Zheng has published more than 30 research papers.
|Research Interest(s)||Clinical and basic research in hepatobiliary and pancreas carcinoma|
Sep. 2001 – Jun. 2004 Sun Yat-sen University of Medical Sciences, Guangzhou, P.R.China Doctor of Medicine with a specialty in Oncology
Sep. 1996 – Jun. 1999 Sun Yat-sen University of Medical Sciences, Guangzhou, P.R.China Master of Medicine with a specialty in Oncology
Sep. 1991 - Jun.1996 Sun Yat-sen University of Medical Sciences, Guangzhou, P.R.China Bachelor of Medicine
1. Liu, Yingjun; Li, Shengping; Wan, Xiangbin; Li, Yi; Li, Binkui; Zhang, Yaqi; Yuan, Yunfei; Zheng, Yun* (Corresponding author). Efficacy and safety of thermal ablation in patients with liver Metastases. European Journal of Gastroenterology & Hepatology (accepted, Published Ahead-of-Print) European Journal of Gastroenterology & Hepatology. 25(4):442-446, 2013.
2. Y. Liu, Y. Zheng*(Corresponding author), S. Li, B. Li, Y. Zhang, Y. Yuan. Percutaneous Microwave Ablation of Larger Hepatocellular Carcinoma, Clinical Radiology,68: 21-26, 2013.
3. Yunguang Tong, Yun Zheng, Jin Zhou, Nelson M Oyesiku, H. Phillip Koeffler and Shlomo Melmed, Genomic characterization of human and rat prolactinomas, Endocrinology August, 153(8):3679–3691, 2012.
4. Wenwen Chien, Dhong Hyun Tony Lee, Zheng Yun, Peer Wuensche, Rosie Alvarez, Ding Ling Wen, Ahmed M. Aribi, SuMing Thean, Ngan B.Doan, Jonathan W, Said, H.Phillip Koefflerl. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Molecular Carcinogenesis, Article first published online: 8 MAR 2013.
5. Zheng Yun, Lao Xiang-Ming, Zhang Hai-Yan, et al. In vitro and in vivo investigations of Carbon-coated iron nanocrystal combined with EADM [J]. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Feb;28(2):176-9. Chinese.
6. Lao XM, Zhang HY, Li JQ, Chen YM, Chen MS, Yuan YF, Zhang YQ, Zheng Y*(corresponding author). Acute toxicity of carbon-coated iron nanocrystal and its effect on liver and kidney functions and hematological system. Nan Fang Yi Ke Da Xue Xue Bao. 2007 Oct;27(10):1471-5. Chinese.
7. Zhang Hai-Yan, Zheng Yun, Zhou Chun, et al. Physical performance of carbon-coated iron nanoparticles as drug carrier system with magnetic targeting [J]. Acta biophysica sinica, 2006,22(4): 310-316.
8. Zheng Yun, Chen Min-Shan, Li An-Hua, et al. Clinical trial: a new procedure of PMCT under artificial hydrothorax for patients with liver tumors in the hepatic dome. Chinese Journal Of Cancer, 2005,24(9):inside back cover.
9. Zheng Yun, Zhang Ya-Qi, Zou Ru-Hai, et al. Artificial hydrothorax in aid of sonographically guided local therapy for liver tumors in the hepatic dome [J]. Journal of Sun Yat-Sen University (Medical Sciences), 2005,26(6):696-9.
10. Zheng Yun, Li Jin-Qing, Chen Min-Shan, et al.Comparison of shaft temperature related treatment efficacy between “Are-Cooled” microwave coagulation and traditional microwave coagulation [J]. Chinese Journal Of Cancer, 2004,23(11s): 1477-81.
11. Zheng Yun, Li Jin-Qing, Zhang Ya-Qi, et al. Sonographically guided percutaneous “Air-Cooled” microwave coagulation treatment of liver cancer: an experimental study [J]. Chinese Journal Of Cancer ,2004,23(6): 609-3.
12. Lao Xiang-Ming, Zheng Yun, Chen Yi-Ming, et al. Carbon-coated iron nanocrystals combined with EADM for liver malignancies treatment------an experimental study [J]. Chinese Journal of Pathophysiology,2007, 23 (5) : 1037 – 40.
13. Lao XM, Zhang HY, Li JQ, Chen YM, Huang JT, Zhang YQ, Zheng Y*(corresponding author). Adsorption and sustained release of epirubicin from carbon-coated iron nanocrystals. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(8):1331-4. Chinese.
14. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8.
15. Chen MS，Zheng Y. Combining with Radiofrequeney Ablation and Ethanol Injection for treatment of patients with liver cancer. Chinese Journal Of Cancer,2001,20(7)：759—76.
16. Lu Ming-De, Zheng Y, Huang Jia-Ling, et al. Immune responses induces by hepG2 cells expressing B7-1 or IL12 molecules [J] Chin J Bases Clin General Surg, 2000,7(4):208-210.
17. Chen MS, Zheng Y, Zhang YQ, et al. Combining with radiofrequency ablation and ethanol injection for treatment of patients with liver cancer [J]. Chinese Journal Of Cancer, 2001,20(7): 759-761
18. Zheng Y, Lu MD, Chen JW, et al. Experimental study of suppress effect of microwave coagulation on the reinoculated H22 cell [J]. Chinese Journal Of Cancer, 2000,19(17): 646-648.
Updated by International Office, Sun Yat-sen University Cancer Center
Dr. Wei Wei is associate professor of Department of Hepatobiliary Tumor of Sun Yat-sen University Cancer Center. Dr. Wei obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 2000 and 2008, respectively. From 2000, Dr.Wei was engage in the clinical and theoretical research of hepatobiliary tumor. In Apr 2008, Dr.Wei has participated the PATH project (Program For The Advancement of Therapy in Hepatocellular carcinoma) in Barcelona for a week. And he worked as visiting bachelor in Department of HPB and National Liver Transplantation Center of Austin Hospital of University of Melbourne from Mar 2009 to Sep 2009. Dr.Wei now is a main member of the research team in Department of Hepatobiliary Tumor and specialize in diagnosis and treatment of hepatobiliary tumor, including surgery, vascular intervention, local ablation and liver transplantation. The work of Dr.Wei and his team has got support by different fund including National natural science foundation of China and has published more than 10 SCI papers.
Diagnosis and treatment of hepatobiliary tumor, including surgery, vascular intervention, local ablation, target therapy and liver transplantation, especially the multidisciplinary treatments for advanced HCC.
1995-2000 Faculty of clinical medicine of Sun Yat-sen University of Medical Sciences, Bachelor
2003-2005 Faculty of Clinical Oncology of Sun Yat-sen University, Master
2005-2008 Faculty of Clinical Oncology of Sun Yat-sen University, PhD
1. Chen ZY, Wei W, Guo ZX, Peng LX, Shi M, Li SH, Xiao CZ, Zhong C, Qian CN, Guo RP*. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer. 2014 Feb 4;110(3):733-40.
2. Li SH, Wei W, Guo RP*, Shi M, Guo ZX, Chen ZY, Xiao CZ, Cai MY, Zheng L. Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors. Med Oncol. 2013 Dec;30(4):696.
3. Chen ZY, Shi M, Peng LX, Wei W, Li XJ, Guo ZX, Li SH, Zhong C, Qian CN, Guo RP. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis. J Transl Med. 2012 Dec 10;10:245
4. Chen ZY, Wei W, Guo ZX, Lin JR, Shi M, Guo RP*. Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection. J Gastroenterol Hepatol. 2011 May;26(5):866-74.
5. Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F, Qiu MZ, Li FH, Yan SL, Zeng MS, Huang P, Xu RH. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol Rep. 2010 Jun;23(6):1735-45.
Updated by International Office, Sun Yat-sen University Cancer Center
Dr. Hu Dandan graduated as an MD in Clinical Medicine (8-year program) from Tsinghua University - Peking Union Medical College. She has visiting experience at Massachusetts General Hospital and MD Anderson Cancer Center. She was also an exchange student at the Prince of Wales Hospital, Hong Kong (2016). She is a member of the Liver Cancer Committee of Guangdong Anti-Cancer Association, a member of the Society of American Gastrointestinal Endoscopic Surgeons (SAGES), and assistant editor of Hepatobiliary Surgery and Nutrition. She also won the APA Annual Meeting Young Scholar Award (2019), and has published more than 10 SCI papers in Gut and other internationally recognized journals as a first author (co-author) or corresponding author (co-correspondent). Dr. Hu Dandan is also a certified interpreter by the National Ministry of Personnel, serving as a simultaneous interpreter for international hepatobiliary and pancreatic congresses.
The multidisciplinary treatment of hepatobiliary tumors, minimally invasive surgery, second-generation sequencing and precision treatment of primary and metastatic liver cancers.
M.D. Peking Union Medical College, China, 2009-2017
1. Yang H#, Sun L#, Pang Y#, Hu D#, Xu H, Mao S, Peng W, Wang Y, Xu Y, Zheng Y C, Du S, Zhao H, Chi T, Lu X, Sang X, Zhong S, Wang X, Zhang H, Huang P*, Sun W*, Mao Y*. Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure. Gut, 2020. doi:10.1136/gutjnl-2019-319960. (IF: 19.819)
2. Hu D#, Xie Z#, Ye Y, Bahijri S, Chen M*. The beneficial effects of intermittent fasting: an update on mechanism, and the role of circadian rhythm and gut microbiota. Hepatobiliary Surg Nutr 2020;9(5):597-602. doi: 10.21037/hbsn-20-317 (IF: 5.296)
3. Yuqian Ye#, Haopeng Xu#, Zhibo Xie, Lun Wang, Yuning Sun, Huayu Yang, Dandan Hu*, Yilei Mao*. Time-Restricted Feeding Reduces the Detrimental Effects of a High-Fat Diet, Possibly by Modulating the Circadian Rhythm of Hepatic Lipid Metabolism and Gut Microbiota [J]. Front Nutr, 2020, 7(596285. (IF: 3.365)
4. Pan Y-X#, Fu Y-Z#, Hu D-D#, Long Q, Wang J-C, Xi M, Liu S-L, Xu L, Liu M-Z, Chen M-S and Zhang Y-J (2020) Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis. Front. Oncol. 10:1639. doi: 10.3389/fonc.2020.01639 (IF: 4.848)
5. Jinjun Ren#, Dandan Hu#, Huayu Yang, Wenjun Liao, Wei Xu, Penglei Ge; Hongbing Zhang; Xinting Sang; Xin Lu; Shouxian Zhong, Yilei Mao*. Alteration in gut microbiota caused by time-restricted feeding alleviate hepatic ischaemia reperfusion injury in mice [J]. J Cell Mol Med, 2019, 23(3): 1714-1722. (IF: 4.427)
Updated March 2021 by International Office, Sun Yat-sen University Cancer Center